Mohammed Milhem

Mohammed Milhem, MBBS, is a Clinical Professor in the Department of Internal Medicine at the University of Iowa's Carver College of Medicine. He is a key leader in oncology research and clinical care, serving as the Associate Director of Clinical Research at the Holden Comprehensive Cancer Center and Director of the Melanoma Program. His work spans melanoma, sarcoma, immunotherapy, and experimental therapeutics.

Research Interests: Dr. Milhem's research focuses on improving outcomes in melanoma and sarcoma through immunotherapy, particularly anti-PD-1 agents, and understanding factors influencing treatment response such as antibiotic use and immune-related adverse events. He investigates novel combination therapies including radiation with immunotherapy and targeted agents like pazopanib. His work also explores wound morbidity in sarcoma patients undergoing radiotherapy and the role of natural killer cells in uveal melanoma.

Publication Trends: His recent publications (2020–2021) are predominantly clinical and translational, appearing in journals like Cancer, Cancers (Basel), and Melanoma Research. These reflect a strong emphasis on phase II trials, retrospective analyses, and case reports in sarcoma and melanoma, with a focus on immunotherapy efficacy, toxicity, and predictive biomarkers.

Leadership & Clinical Roles:

• Holden Chair of Experimental Therapeutics
• Associate Director of Clinical Research, Holden Comprehensive Cancer Center
• Director, Melanoma Program, Holden Comprehensive Cancer Center

Education:

• MBBS, Jordan University, Amman, Jordan
• Residency, Internal Medicine, University of Illinois at Chicago
• Fellowship, Hematology/Oncology, University of Illinois at Chicago
• Fellowship, Bone Marrow Transplant, University of Illinois at Chicago

Professional Certifications:

• American Board of Internal Medicine
• American Board of Internal Medicine, Hematology
• American Board of Internal Medicine, Oncology

Advising and Grants: While specific students and grants are not mentioned in the text, Dr. Milhem leads major clinical research initiatives and directs therapeutic programs, suggesting active mentorship and grant-funded research. His role as Holden Chair indicates significant research support.

Labs and Teams: Dr. Milhem collaborates extensively within the Holden Comprehensive Cancer Center, particularly in melanoma and sarcoma multidisciplinary teams. He is affiliated with research groups focused on immunotherapy, clinical trials, and experimental therapeutics.